drugset / Trial / NCT05957081
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
Phase 1
Recruiting
67 enrolled
PharmAbcine
Merck Sharp & Dohme LLC · collabNovotech (Australia) Pty Limited · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1a/1b, first-in-human (FIH), open label study to evaluate the safety, tolerability, and pharmacokinetics (PK) of PMC-309, a mAb against the human VISTA ligand, in participants with advanced or metastatic solid tumors administered as a monotherapy and in combination with pembrolizumab.
Timeline
- Start
- 2024-01-03
- Primary completion
- 2029-10-30
- Completion
- 2030-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PMC-309 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.